General Information of Drug (ID: DMOS9NZ)

Drug Name
PF-03882845 Drug Info
Synonyms
UNII-34ZKU73FU3; 34ZKU73FU3; CHEMBL1215331; 1023650-66-9; PF-3882845; (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid; compound 2 [PMID: 24738581]; SCHEMBL552307; GTPL9061; DTXSID70144940; XNULRSOGWPFPBL-REWPJTCUSA-N; (+/-)-(3SR,3aRS)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid; BDBM50324210; ZINC58583489; DB11814; NCGC00485023-01; PF-03882845, &gt
Indication
Disease Entry ICD 11 Status REF
Diabetic nephropathy GB61.Z Terminated [1]
Cross-matching ID
PubChem CID
46871935
CAS Number
CAS 1023650-66-9
TTD Drug ID
DMOS9NZ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mineralocorticoid receptor (MR) TT26PHO MCR_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Mineralocorticoid receptor (MR) DTT NR3C2 5.85 7.414 6.42 7.379
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic nephropathy
ICD Disease Classification GB61.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mineralocorticoid receptor (MR) DTT NR3C2 7.31E-01 -5.31E-04 -1.53E-03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of Pfizer (2011).
2 Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.J Med Chem.2010 Aug 26;53(16):5979-6002.